A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subject
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.
| Condition(s) | Advanced Solid Tumors |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors. |
| Who can participate | Inclusion Criteria: 1. Voluntary participation and written informed consent; 2. 18-75 years older, no gender limitation; 3. Eastern Cooperative Oncology Group (ECOG) score: 0-1; 4. With a life expectancy ≥ 3 months; 5. Pathologically diagnosed advanced solid tumor; 6. Be able to provide fresh or archived tumour tissue; 7. At least one measurable lesion according to RECIST v1.1; 8. Adequate bone marrow reserve and organ function; 9. Contraception is required during clinical trials, and pregnancy tests must be negative for women of childbearing age within 7 days before the first dose. Exclusion Criteria: 1. Meningeal metastasis history or clinical symptoms of central nervous system metastasis; 2. Previous or co-existing malignancies; 3. Spinal cord compression that was not treated radically |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Locations | Guangzhou, Guangdong, China |
| Start date | 2025-02-18 |
| NCT ID | NCT06703177 |
| Official listing | https://clinicaltrials.gov/study/NCT06703177 |